Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dark shadows of screen: How Dark Tetrad traits, social identity, and binge-watching fuel digital fatigue.

Acta psychologica·2026
Same author

Amino alkyl-alkyl/aryl sulphides (DRDE-07 and analogues) as promising cytoprotectants for sulphur and nitrogen mustards - A review.

Toxicology reports·2025
Same author

Oxygen vacancies mediated enhanced photocatalytic activity of band gap engineered BaSn<sub>1-<i>x</i></sub> Cu <sub><i>x</i></sub> O<sub>3</sub> towards methylene blue degradation under visible and sunlight.

RSC advances·2025
Same author

Exploring workplace spirituality, mindfulness, digital technology, and psychological well-being: A complex interplay in organizational contexts.

Acta psychologica·2024
Same author

Probing the molecular interactions between cholinium-based ionic liquids and insulin aspart: A combined computational and experimental study.

International journal of biological macromolecules·2023
Same author

Spectrophotometric Analysis of Fluoride Concentration in Dentifrices for Children in India.

Journal of pharmacy & bioallied sciences·2022
Same journal

Repurposing-inspired discovery of novel sagitta-shaped covalent TEAD inhibitors from NSAID diflunisal.

European journal of medicinal chemistry·2026
Same journal

Antiviral drug discovery for enterovirus 71: structure-based optimization of direct and host-targeted strategies.

European journal of medicinal chemistry·2026
Same journal

Rational design and synthesis of TBC1D2 inhibitors: Augmenting autophagy to improve sorafenib sensitivity in hepatocellular carcinoma.

European journal of medicinal chemistry·2026
Same journal

Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells.

European journal of medicinal chemistry·2026
Same journal

Corrigendum to "Discovery of Benfotiamine as a subnanomolar P2Y<sub>14</sub>R antagonist for inflammatory diseases via drug repurposing and molecular dynamics-guided mechanism elucidation" [Eur. J. Med. Chem. 316 (2026) 119068].

European journal of medicinal chemistry·2026
Same journal

Identification of 3-arylquinoxalin-2(1H)-one derivatives targeting BRD4 BD1 as efficient anticancer agents.

European journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

New diketone based vanadium complexes as insulin mimetics.

A Sheela1, S Mohana Roopan, R Vijayaraghavan

  • 1Chemistry Division, School of Science and Humanities, VIT University, Vellore 632 014, Tamil Nadu, India.

European Journal of Medicinal Chemistry
|March 14, 2008
PubMed
Summary
This summary is machine-generated.

New vanadium complexes show promising antidiabetic activity. These compounds, bisdimethylmalonatooxovanadium(IV) and bisdiethylmalonatooxovanadium(IV), demonstrate potential as therapeutic agents for diabetes management.

More Related Videos

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Area of Science:

  • Inorganic Chemistry
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Vanadium compounds, particularly oral vanadate, have demonstrated insulin mimetic activity since 1985.
  • Vanadium complexes are being investigated as potential therapeutic agents for diabetes.
  • Diketone-based vanadium complexes are a focus for antidiabetic drug development.

Purpose of the Study:

  • To synthesize and characterize two new diketone-based vanadium complexes: bisdimethylmalonatooxovanadium(IV) and bisdiethylmalonatooxovanadium(IV).
  • To evaluate the in vivo antidiabetic activity of these novel vanadium complexes.
  • To compare their efficacy against a standard antidiabetic drug and a previously studied vanadium complex.

Main Methods:

  • Synthesis of bisdimethylmalonatooxovanadium(IV) and bisdiethylmalonatooxovanadium(IV).
  • Characterization using UV-visible, FTIR, and mass spectral analyses.
  • In vivo animal studies to assess antidiabetic potential.

Main Results:

  • Successful synthesis and characterization of the two new vanadium complexes.
  • Demonstration of significant antidiabetic activity in animal models.
  • Comparable efficacy to a standard antidiabetic drug and bisacetylacetonatooxovanadium(IV).

Conclusions:

  • Bisdimethylmalonatooxovanadium(IV) and bisdiethylmalonatooxovanadium(IV) possess notable antidiabetic properties.
  • These novel vanadium complexes represent potential candidates for future diabetes therapies.
  • Further research into diketone-based vanadium complexes is warranted for diabetes treatment.